Hengeler Mueller advised CELLINK on the transaction.
Swedish CELLINK AB has entered into an agreement with the shareholders of German Nanoscribe Holding GmbH on the acquisition of all outstanding shares in the company for a purchase price on a cash- and debt-free basis of approximately EUR 34 million as fixed purchase price and approximately EUR 16 million in earn-outs.
Nanoscribe is a market leading and award-winning company focusing on development of high-precision 3D printers based on Two-Photon Polymerization technology. Approximately 35% of the fixed purchase price of EUR 34 million will be paid in newly issued shares of series B in CELLINK, the remaining portion will be paid cash.
CELLINK is the world-leading bioconvergence company creating the future of medicine by providing technologies, products and services to create, understand, and master biology.
The Hengeler Mueller team was led by partners Hans-Jörg Ziegenhain (Picture) and Elisabeth Kreuzer (both Corporate/M&A) and included partners Markus Ernst (Tax) (all Munich), Dirk Uwer (Public Law, Düsseldorf) and Hendrik Bockenheimer (Employment, Frankfurt), counsel Jakub Lorys (Corporate/M&A, Munich), Susanne Koch (Public Law) and Patrick Wilkening (IP/IT) (both Düsseldorf) as well as associates Johannes Schmidt, Ioanna Tsotsa (both Corporate/M&A), Verena Klosterkemper (Tax) (all Munich), Patrick Schmidt (IP/IT) and Selina Rohr (Employment) (both Frankfurt).
Involved fees earner: Hendrik Bockenheimer – Hengeler Mueller; Markus Ernst – Hengeler Mueller; Verena Klosterkemper – Hengeler Mueller; Susanne Koch – Hengeler Mueller; Elisabeth Kreuzer – Hengeler Mueller; Jakub Lorys – Hengeler Mueller; Selina Rohr – Hengeler Mueller; Johannes Schmidt – Hengeler Mueller; Patrick Schmidt – Hengeler Mueller; Ioanna Tsotsa – Hengeler Mueller; Dirk Uwer – Hengeler Mueller; Patrick Wilkening – Hengeler Mueller; Hans-Jörg Ziegenhain – Hengeler Mueller;
Law Firms: Hengeler Mueller;
Clients: Cellink AB;